EGFR and neoplasm: Finally, Epidermal Growth Factor Receptor (EGFR) mutations, which are major oncogenic drivers in lung carcinoma tumours exhibiting predominant lepidic growth [24], were not assessed, as collection of biological materials was not included in the design of the 2 associated trials, which were designed before these mutations were discovered.